Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Alkermes Q3 2026 Results: Net Income $16.3M, Down 80.3% YoY

Alkermes plc reported a significant increase in cash and cash equivalents to $631.3 million as of September 30, 2026, compared to $388.6 million at year-end 2025. The company's intangible assets grew substantially from $0.8 million to over $1.74 billion, reflecting the impact of the Avadel Acquisition and its expanded neuroscience portfolio including LUMRYZ.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue480.1394.2
Profit before tax14.7100.7
Net income16.382.8
EPS (diluted, $ a share)$0.09$0.49

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-80.3%
Revenue, year on year+21.8%
Operating margin7.5%
Source

10-Q filed with the SEC, NASDAQ: ALKS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Alkermes plc.: key numbers

Share price
$46.53Close, Nov 16
Market cap
$7.82B
Shares outstanding
168.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Alkermes plc.

All →
7:04 AM ET 8-K
Court & Legal Update

Alkermes Court & Legal Update

Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.

Counterparty
Teva Pharmaceuticals, Inc.
7:18 PM ET Form 4
Insider Selling

Alkermes EVP, CLO, Alkermes, Inc. David Joseph Gaffin Sells $94K of Stock

David Joseph Gaffin, EVP, CLO, Alkermes, Inc., sold 2,035 shares of Alkermes plc. at $46.17 a share, worth $94K in total on Nov 3, 2026. Shares held after the trade: 219,353 (-0.9%).

Value
$94K
Shares
2,035
Price
$46.17
Role
EVP, CLO, Alkermes, Inc.
Holding change
-0.9%
Trade date
Nov 3, 2026
8:10 AM ET 8-K
Financial Results

Alkermes Financial Results

Alkermes plc reported third quarter 2026 total revenues of $480.1 million, driven by solid performance in its proprietary product portfolio including VIVITROL and LUMRYZ. The company reported GAAP net income of $16.3 million and reaffirmed its full-year 2026 financial expectations while highlighting progress in its orexin development programs.

Term
3 months

“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions.”

Blair Jackson, President and Chief Executive Officer
6:22 PM ET Form 4
Insider Selling

Alkermes EVP, CLO, Alkermes, Inc. David Joseph Gaffin Sells $83.5K of Stock

David Joseph Gaffin, EVP, CLO, Alkermes, Inc., sold 2,034 shares of Alkermes plc. at $41.03 a share, worth $83.5K in total on Oct 2, 2026. Shares held after the trade: 221,388 (-0.9%).

Value
$83.5K
Shares
2,034
Price
$41.03
Role
EVP, CLO, Alkermes, Inc.
Holding change
-0.9%
Trade date
Oct 2, 2026
7:12 AM ET 8-K
Clinical Trial Data

Alkermes Clinical Trial Data

Alkermes announced positive topline results from a Phase 1b proof-of-concept study for ALKS 7290, a novel orexin 2 receptor agonist for the treatment of ADHD. The study demonstrated clinically meaningful improvements in ADHD symptoms as measured by the AISRS and CGI-S scales, marking the first clinical evidence of an orexin agonist's efficacy in ADHD. A Phase 2 study is currently enrolling with data expected in 2027.

9:12 AM ET 8-K
Leadership Change

Alkermes Leadership Change

Alkermes plc has appointed Anne C. Whitaker to its Board of Directors, effective September 14, 2026, increasing the board size to 11 members. Ms. Whitaker, a seasoned biopharmaceutical executive, will receive an initial new director equity award with a target value of $600,000. Her appointment is intended to support the company's strategic focus on its neuroscience pipeline and commercial growth.

Counterparty
Anne C. Whitaker

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.